Literature DB >> 24425686

Mutational spectrum defines primary and secondary myelofibrosis.

Ken I Mills1, Mary Frances McMullin.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24425686      PMCID： PMC4007941          DOI： 10.3324/haematol.2013.101279

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  18 in total

1.  The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction.

Authors:  Pipsa Saharinen; Olli Silvennoinen
Journal:  J Biol Chem       Date:  2002-09-25       Impact factor: 5.157

2.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

3.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

4.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

Review 5.  Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies.

Authors:  Ulrike Bacher; Claudia Haferlach; Susanne Schnittger; Alexander Kohlmann; Wolfgang Kern; Torsten Haferlach
Journal:  Ann Hematol       Date:  2010-03-02       Impact factor: 3.673

6.  A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Authors:  Robert Kralovics; Francesco Passamonti; Andreas S Buser; Soon-Siong Teo; Ralph Tiedt; Jakob R Passweg; Andre Tichelli; Mario Cazzola; Radek C Skoda
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

7.  A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

Authors:  Francesco Passamonti; Francisco Cervantes; Alessandro Maria Vannucchi; Enrica Morra; Elisa Rumi; Arturo Pereira; Paola Guglielmelli; Ester Pungolino; Marianna Caramella; Margherita Maffioli; Cristiana Pascutto; Mario Lazzarino; Mario Cazzola; Ayalew Tefferi
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

8.  Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.

Authors:  Philip A Beer; François Delhommeau; Jean-Pierre LeCouédic; Mark A Dawson; Edwin Chen; David Bareford; Rajko Kusec; Mary Frances McMullin; Claire N Harrison; Alessandro M Vannucchi; William Vainchenker; Anthony R Green
Journal:  Blood       Date:  2009-12-11       Impact factor: 22.113

9.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

Authors:  Francisco Cervantes; Brigitte Dupriez; Arturo Pereira; Francesco Passamonti; John T Reilly; Enrica Morra; Alessandro M Vannucchi; Ruben A Mesa; Jean-Loup Demory; Giovanni Barosi; Elisa Rumi; Ayalew Tefferi
Journal:  Blood       Date:  2008-11-06       Impact factor: 22.113

10.  Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F.

Authors:  Franz X Schaub; Roland Jäger; Renate Looser; Hui Hao-Shen; Sylvie Hermouet; François Girodon; Andre Tichelli; Heinz Gisslinger; Robert Kralovics; Radek C Skoda
Journal:  Blood       Date:  2008-12-01       Impact factor: 22.113
View more
  2 in total

Review 1.  The Hematopoietic Niche in Myeloproliferative Neoplasms.

Authors:  Annette H Schmitt-Graeff; Roland Nitschke; Robert Zeiser
Journal:  Mediators Inflamm       Date:  2015-11-30       Impact factor: 4.711

Review 2.  Emerging agents and regimens for polycythemia vera and essential thrombocythemia.

Authors:  Rory M Shallis; Nikolai A Podoltsev
Journal:  Biomark Res       Date:  2021-05-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.